Anemia, Sickle Cell, Anemia; Sickle-Cell, With Crisis
Conditions
Brief summary
This study will investigate the safety, tolerability and potential for the use of up to three daily doses of 30-40 mg/kg HU (daily) upon hospitalization for painful vaso-occlusive crises .
Detailed description
Sickle cell anemia (SCA) is a hereditary hemoglobinopathy; complications of the disease include, spleen enlargement, acute chest syndrome, pulmonary hypertension, stroke and cumulative damage to multiple organs, and painful vaso-occlusive crises (VOC). In Brazil, about 3,500 children are born each year with DF, and the number of individuals with sickle cell disease (DF) in the country is estimated between 25,000 and 30,000 (ANVISA 2012; BRAZIL, 2012). Hydroxyurea (HU, or hydroxycarbamide) is the only drug approved to date by the American FDA for use in adults with sickle cell disease. The drug modifies the disease process, improving hematological parameters and the hospitalization time of patients, as well as the frequency of vaso-occlusive crises.In addition to its proven effects during chronic use, experimental data indicate that HU has immediate anti-inflammatory effects. In addition to its proven effects during chronic use, experimental data indicate that HU has immediate anti-inflammatory effects. This study will investigate the safety, tolerability and potential for the use of up to three daily doses of 30-40 mg/kg HU (daily) upon hospitalization for VOC.
Interventions
DRUGHydroxyurea
Patients hospitalized for uncomplicated pain crisis with a pain scale of ≥ 6 during the last 24 hours will receive a dose of 30-40 mg / kg hydroxyurea. This same dose of hydroxyurea will be repeated at 24 h and 48 h after the first dose of hydroxyurea, with dose suspension if the patient is discharged within 48 hours. Patients will also receive the center's usual practice and analgesia protocol.
Sponsors
Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Confirmed diagnosis of homozygous sickle cell anemia (HbSS). * Hospitalization due to onset of uncomplicated vaso-occlusive crisis (with pain scale≥6 within the last 24 h), confirmed by clinical evaluation. * Documented and written informed consent
Exclusion criteria
* Confirmed or suspected pregnancy. * Initiation of painful crisis\> 72h. * Blood transfusion during the last 8 weeks. * Admission to Emergency Room due to pain in the last 4 weeks. * Neutrophil count \<2.5 x 109/L or platelet count \<95.0 x 109 / L or Hb \<4.5 g / dL * Weight \<38 Kg or\> 95 Kg. * Interval longer than 8h since arrival at center. * Non-consent to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-related adverse events | up to 15 days post last dose | as assessed by CTCAE version 4.03 |
| Number of participants with altered laboratory values related to treatment | up to 15 days post last dose | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total opioid use (mg of IV morphine) | From study inclusion until hospital discharge (average, up to 7 days post admission) | — |
| Pain score | From admission until hospital discharge (average, up to 7 days post admission) | Numeric pain score rating (0 to 10; 0 = no pain, 10 = worst pain) |
| Time until hospital discharge | Average, up to 7 days post admission | — |
Countries
Brazil
Contacts
Primary ContactClarisse Lobo, MD
Outcome results
None listed